Best HIV Medication: What Doctors Recommend Now

For most adults newly diagnosed with HIV, doctors now recommend a regimen built around one of two integrase strand transfer inhibitors: bictegravir or dolutegravir, combined with one or two backbone drugs from the nucleoside reverse transcriptase inhibitor class.¹ These regimens suppress the virus reliably, come with a high barrier to resistance, and for most people cause relatively few side effects. But “best” depends on circumstances that vary from person to person, including weight concerns, pregnancy plans, kidney health, co-infections, and whether swallowing a daily pill is realistic long-term.

Why Integrase Inhibitors Lead the Pack

HIV treatment has evolved through several generations of drug classes. Integrase inhibitors are the newest to reach widespread use, and they have displaced older classes like protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs) at the top of treatment guidelines. The reason comes down to how the virus replicates. After HIV enters a cell, it needs to splice its own genetic material into the host cell’s DNA. Integrase inhibitors block the enzyme responsible for that splicing step, trapping the viral machinery before it can complete the job.² Because the drug essentially locks the virus out of the cell’s genome at a critical moment, resistance is harder to develop and viral loads drop quickly after starting treatment.³

Within this class, bictegravir and dolutegravir have emerged as the preferred options because they combine strong antiviral activity with a particularly high genetic barrier to resistance. Older integrase inhibitors like raltegravir still work but require twice-daily dosing, and elvitegravir needs a pharmacologic booster that introduces more drug interactions. Bictegravir and dolutegravir avoid those drawbacks, which is why the 2024 International Antiviral Society–USA panel puts them at the center of first-line recommendations.¹

The Most Prescribed Single-Tablet Regimens

Most people starting HIV treatment today receive a single-tablet regimen, meaning all the drugs they need are combined into one pill taken once daily. The most widely prescribed is Biktarvy, which packages bictegravir with emtricitabine and tenofovir alafenamide (TAF). Its popularity stems from a combination of practical advantages: a small pill, few drug interactions, strong tolerability, and a high barrier to resistance.⁴ In clinical trials, switching to Biktarvy from other regimens maintained viral suppression in virtually all participants who remained in the study, and the switch was safe and well tolerated.⁵

Triumeq, which combines dolutegravir with abacavir and lamivudine, was once the dominant single-tablet regimen but has been somewhat overtaken by Biktarvy, partly because abacavir requires a genetic test to rule out a hypersensitivity reaction before prescribing. Another option, Genvoya, pairs elvitegravir with cobicistat, emtricitabine, and TAF, though the cobicistat booster introduces more potential drug interactions. Research comparing these single-tablet options head-to-head has found that Biktarvy, Genvoya, and Dovato all achieved good safety profiles and high rates of viral suppression.⁶

Two-Drug Regimens as a Lighter Alternative

The traditional approach to HIV treatment uses three active drugs, but in recent years a simpler two-drug combination has gained ground. Dovato pairs dolutegravir with lamivudine in a single tablet. Multiple large randomized trials have shown that certain two-drug regimens perform just as well as three-drug regimens at keeping the virus suppressed, and the side-effect differences generally reflect what you’d expect from the individual drugs involved.⁷ The dolutegravir-lamivudine combination specifically has shown durable effectiveness, good tolerability, and a high barrier to viral resistance, which is why it earned a place among first-line options.⁸

Why would fewer drugs matter? Less medication means fewer potential side effects and fewer chances for drug interactions, especially relevant for people taking medications for other conditions. It can also mean a smaller pill and sometimes a lower cost. There is a catch, though: the two-drug approach is not recommended if you have hepatitis B co-infection (because stopping certain HIV drugs can cause a hepatitis B flare, as discussed below) or if your viral load has not yet been confirmed to be low enough. Your doctor will evaluate whether you are a candidate based on resistance testing and other factors.

TAF Versus TDF and Why It Matters for Your Kidneys and Bones

Many HIV regimens include a drug called tenofovir as a backbone, but tenofovir comes in two formulations that behave quite differently in the body. The older version, tenofovir disoproxil fumarate (TDF), delivers higher drug levels to the kidneys and bones, which over years can erode bone mineral density and strain kidney function. The newer version, tenofovir alafenamide (TAF), reaches the same cells HIV infects but exposes the kidneys and bones to much less drug. A network meta-analysis found that TDF caused greater drops in kidney filtration and bone density compared with TAF.⁹

That distinction is especially important for people who have had kidney trouble on TDF. In a study following individuals who actually developed a form of kidney toxicity while taking TDF, switching to TAF and being followed for five years showed no recurrence of the problem, with kidney markers, protein in the urine, and bone density at the lumbar spine all remaining stable.¹⁰ This is why almost all current first-line single-tablet regimens use TAF rather than TDF. The exception is generic formulations in lower-income countries, where TDF-based regimens remain common because TAF is more expensive.

The Weight Gain Question

One issue that has complicated the dominance of integrase inhibitors is weight gain. A growing body of evidence from large observational studies and randomized trials has consistently shown that integrase inhibitors, particularly dolutegravir and bictegravir, are associated with more weight gain than older drug classes. In the AFRICOS cohort from four African countries, people on dolutegravir-based treatment were about twice as likely to have a body mass index above 25 compared to those on non-integrase regimens. Randomized trials in South Africa and Cameroon confirmed significant weight gain with dolutegravir, with differences appearing as early as four weeks and persisting through nearly four years of follow-up. The effect was greatest among women and when dolutegravir was combined with TAF.¹¹

Research into why this happens is still evolving. One recent study explored whether the gut microbiome plays a role, identifying specific bacterial taxa that were either positively or negatively associated with weight gain in people taking integrase inhibitors.¹² For now, no one has pinpointed a single mechanism, and the weight gain does not happen to everyone. But it is real enough that clinicians factor it into treatment decisions, especially for patients who already have metabolic risk factors. If weight gain becomes problematic, switching to a non-integrase-based regimen or to cabotegravir (the one integrase inhibitor that has not shown the same weight signal in trials) is sometimes considered.

The Abacavir and Heart Risk Debate

Abacavir, one of the backbone drugs in the combination pill Triumeq, has been linked to cardiovascular risk. Research has associated abacavir-containing regimens with vascular dysfunction and increased cardiovascular risk.¹³ The story, however, is not clear-cut. A review of studies following the initial alarm found conflicting results: among the larger studies, some concluded there was a real association with heart attacks and others found the link was not robust, with confounding factors like smoking, kidney function, and substance use muddying the picture.¹⁴ No convincing biological mechanism has been established. In practice, many clinicians simply avoid abacavir in patients who already have elevated cardiovascular risk, favoring tenofovir-based regimens instead. For someone without heart risk factors, the choice may come down to other considerations.

Long-Acting Injectables and the End of the Daily Pill

Not everyone can manage or wants to take a daily pill. Long-acting injectable cabotegravir combined with rilpivirine (sold as Cabenuva) lets people receive two intramuscular injections every one or two months instead. This is the first complete HIV treatment regimen that requires no oral medications at all. The injections have maintained viral suppression even in patients with kidney failure, including one who went through a kidney transplant while on the injectable regimen.¹⁵

The injectable option does come with limitations. You need to have an undetectable viral load before switching, it requires regular clinic visits for the shots, and rilpivirine has a lower barrier to resistance than drugs like dolutegravir. Injection-site reactions are common, though they tend to lessen over time. For people who struggle with pill adherence, face stigma around daily medication, or simply prefer fewer reminders of their diagnosis, the convenience and discretion can be transformative.

Lenacapavir and the Capsid Inhibitor Frontier

For people whose virus has developed resistance to multiple drug classes, options used to be extremely limited. Lenacapavir, the first capsid inhibitor approved for HIV, represents a genuinely new mechanism. It attacks the protein shell that surrounds the virus’s genetic material, interfering with multiple steps of the viral life cycle at once. In a trial of people with multidrug-resistant HIV, about four out of five reached an undetectable viral load by six months, and that rate held at two years.¹⁶¹⁷ No serious side effects related to the drug were identified.

Lenacapavir is given as a subcutaneous injection every six months, which is the longest dosing interval of any current HIV treatment. Right now it is approved specifically for people with heavily treatment-experienced, multidrug-resistant HIV. But studies are underway testing it in broader populations, including as a prevention tool. If it eventually reaches first-line use, a twice-yearly injection could reshape the treatment landscape.

HIV Treatment During Pregnancy

Choosing an HIV regimen during pregnancy matters enormously because the right treatment prevents the virus from passing to the baby. Dolutegravir has become the preferred anchor drug in pregnancy because it achieves the highest rates of viral suppression in pregnant individuals, directly reducing the risk of perinatal transmission.¹⁸

Early on, there was concern about a possible link between dolutegravir use around conception and neural tube defects in newborns. This worry came from preliminary data in a surveillance study from Botswana, which triggered cautious guidelines recommending against dolutegravir for women who might become pregnant.¹⁹ However, updated data from the same Tsepamo surveillance study and additional real-world evidence have since found no increased risk of neural tube defects with dolutegravir. Randomized trials and observational studies also report no increased risk of adverse birth outcomes or birth defects overall. Studies of dolutegravir paired with lamivudine during pregnancy showed high rates of viral suppression, no cases of mother-to-child transmission, and no new safety concerns.²⁰ As a result, dolutegravir-based regimens are now recommended for pregnant individuals in current guidelines. Elvitegravir with cobicistat, on the other hand, is generally avoided in pregnancy because drug levels drop significantly, raising the risk of the virus rebounding.

When You Also Have Hepatitis B

Hepatitis B is common among people with HIV because the two viruses spread in similar ways. Co-infection accelerates liver disease and raises the risk of liver cancer and liver-related death compared to having hepatitis B alone.²¹ This makes the choice of HIV regimen especially consequential, because several HIV drugs also fight hepatitis B. Tenofovir (either TAF or TDF) and emtricitabine both have activity against hepatitis B, and lamivudine does too, though resistance develops more readily with lamivudine alone.²²

This dual activity is why Biktarvy is often the go-to for co-infected patients: it covers both viruses in a single tablet. A switch study confirmed that Biktarvy is safe and effective for adults with both HIV and hepatitis B.²³ The two-drug regimen Dovato is generally not a good fit here because it lacks tenofovir, and stopping a hepatitis B-active drug can trigger a dangerous flare of liver inflammation. If you have both infections, your doctor will build a regimen that keeps hepatitis B continuously suppressed alongside HIV.

Starting Treatment Without Delay

Current guidelines encourage starting HIV treatment as soon as possible after diagnosis, sometimes on the same day. The logic is straightforward: faster treatment means faster viral suppression, which improves the individual’s health and eliminates the risk of passing the virus to others. A modeling study estimated that doubling the rate of rapid-start treatment in the United States would avert new transmissions and reduce excess deaths, resulting in net savings to the healthcare system.²⁴

Real-world trials back this up. In a randomized trial in Lesotho, people offered same-day treatment were significantly more likely to be linked to care at three months and to achieve viral suppression at twelve months compared to those given the standard referral process.²⁵ A study in Ethiopia found that same-day initiation achieved viral suppression rates above 90% at six and twelve months.²⁶ Rapid start does require baseline lab work to confirm kidney function and check for hepatitis B, but these tests can be run while the first prescription is already in hand.

What Happens When a Regimen Stops Working

No treatment works forever for every person. When the virus rebounds despite medication, resistance is a likely culprit. In most cases of treatment failure, the virus develops mutations that reduce the drug’s effectiveness. In high-income settings, resistance testing is recommended when the viral load climbs above detectable levels, and a new regimen should include at least two, preferably three, drugs to which the virus is still fully susceptible.²⁷ This is where having drugs from different classes matters: if an integrase inhibitor fails, the doctor may pivot to a protease inhibitor combined with other active agents. And for people who have exhausted multiple classes, lenacapavir now provides a rescue option that did not exist before.

Managing Drug Interactions in Older Adults

Because effective treatment has turned HIV into a manageable chronic condition, a large and growing share of people living with HIV are now over 50. Aging brings other health problems, and with them, other medications. A study of older adults with HIV found that participants were taking a median of 13 medications, with only four of those being antiretrovirals. About half were prescribed at least one potentially inappropriate medication, and 70% had at least one drug interaction serious enough to warrant a change in therapy.²⁸ A third of those interactions were between two non-HIV drugs, meaning the problem is not just about antiretrovirals clashing with other medications; it is about the entire medication list growing unwieldy.

This reality makes low-interaction HIV regimens especially valuable for older patients. Bictegravir and dolutegravir both have relatively clean interaction profiles, which is one reason they are favored. Still, clinicians managing HIV in older adults need to actively review every prescription, supplement, and over-the-counter drug at each visit.²⁹ Simplifying the HIV portion of the regimen, such as switching to a two-drug combination, can reduce overall pill burden and interaction risk.

Financial Barriers and Access to Treatment

Having the best drug on paper means little if you cannot afford it or access it consistently. In the United States, brand-name single-tablet regimens can cost upwards of $3,000 per month without insurance. Most people rely on private insurance, Medicaid, or the federal Ryan White HIV/AIDS Program, which includes AIDS Drug Assistance Programs (ADAPs) at the state level. Yet even with these supports, financial disruptions are common. A survey at a large academic medical center in the southern US found that 10% of patients reported a lapse in their HIV medications over the prior year due to cost or coverage problems. Among those enrolled in ADAP specifically, the rate was about one in five, often triggered by the program’s required semi-annual renewal process and other administrative hurdles.³⁰

The problem is even steeper in lower-income countries. In a cross-sectional survey in Cameroon, 20% of patients on treatment reported difficulty purchasing their antiretroviral drugs in the prior three months. Financial difficulty was strongly associated with lower adherence, which in turn was associated with poorer immune recovery.³¹ Generic manufacturing has driven prices down dramatically for older regimens like TDF-based combinations, and dolutegravir generics are now available in many low- and middle-income countries through licensing agreements. Generic Biktarvy, however, is not yet widely available, which keeps costs higher for the newest preferred regimen.

Digital Adherence Tools

With treatment requiring sustained daily adherence (unless you are on injectables), various digital tools have been developed to help: pill-bottle sensors, smartphone reminders, and real-time monitoring dashboards. The idea is appealing, but the evidence so far is modest. A systematic review and meta-analysis of real-time medication monitoring tools found a small positive effect on adherence that did not reach statistical significance, and no clear improvement in viral suppression.³² Individual studies have shown mixed results, with one trial in China reporting improved adherence and another in Uganda showing a similar trend, but the pooled data remain inconclusive. These tools may help specific individuals who struggle with routine, but they are not a substitute for a regimen that is simple, tolerable, and affordable.

Injectable PrEP for Prevention

While not a treatment for people already living with HIV, pre-exposure prophylaxis (PrEP) is closely related and worth understanding alongside treatment options. Long-acting injectable cabotegravir has been compared head-to-head with the traditional daily oral PrEP pill (tenofovir-emtricitabine) in a randomized trial, with the injectable showing clear results favoring the injection.³³ Beyond efficacy, user experience data tell an interesting story. Satisfaction tended to increase over time among people receiving injectable PrEP while it slightly declined among oral PrEP users. The main challenge for injection users was keeping up with clinic visits, while oral PrEP users struggled more with daily adherence. People on the injectable also reported less stigma: only about 14% felt that people experienced negative judgment due to PrEP use, compared to 29% of oral PrEP users.³⁴ For people at risk who cannot maintain a daily pill habit, the injection is a significant advance in HIV prevention.